LEVIN ARTHUR A
SEC Form 4 insider trading activity
LEVIN ARTHUR A has filed 6 SEC Form 4 filings (7 transaction rows) across 3 companies, including STOK, RNAM, RNA, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Mar 17, 2026.
On the most recent filing, LEVIN ARTHUR A is listed as Director at Stoke Therapeutics, Inc. Inside the rolling window, LEVIN ARTHUR A reported no open-market purchases and 2 open-market sales totaling $150K in STOK and RNA. The largest disclosed transaction in the window is a sale of 1,758 RNA shares on Jan 21, 2026, worth $127K.
Companies traded
Other insiders at STOK
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$150K
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has LEVIN ARTHUR A made?
LEVIN ARTHUR A has filed 6 SEC Form 4 filings (7 transaction rows) across 3 companies, including STOK, RNAM, RNA since 2025.
Which companies does LEVIN ARTHUR A trade?
LEVIN ARTHUR A has filed SEC Form 4 disclosures for 3 companies, including STOK, RNAM, RNA.
When was LEVIN ARTHUR A's most recent SEC Form 4 filing?
LEVIN ARTHUR A's most recent SEC Form 4 filing on Tracefour is dated Mar 17, 2026.
What is LEVIN ARTHUR A's total buy and sell value in the current window?
Inside the rolling retention window, LEVIN ARTHUR A bought $0 and sold $150K based on SEC Form 4 filings.
What was LEVIN ARTHUR A's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,758 RNA shares on 2026-01-21, worth $127K, per SEC Form 4 filings.